How we generate value

Building an exciting pipeline

Highlights

Rejuvenate Biomed and SAS tap AI to develop disease-agnostic drug repurposing discovery tools

Rejuvenate Biomed to accelerate its drug development pipeline of assets for age-related diseases using jointly developed tools

LEARN MORE

Clinical trial demonstrates the therapeutic potential of RJx-01 in sarcopenia

Cutting-edge therapy shows meaningful improvements in muscle strength, function and fatigue resistance, offering hope for millions suffering from sarcopenia.

LEARN MORE

Positive results Phase 1b trial in sarcopenia

Primary and secondary endpoints have been met in this placebo-controlled study in disuse-induced muscle atrophy. RJx-01 was safe and well tolerated and the innovative formulation confirmed excellent pharmacokinetics.

LEARN MORE

Committed to a sustainable future

After identifying 5 core Sustainable Development Goals, Rejuvenate Biomed defined company actions to reach these goals for a sustainable future.

LEARN MORE

Clinical-stage biotech dedicated to the discovery and development of therapeutics to delay the onset of multiple age-related diseases

How we generate value

Building an exciting pipeline

Highlights

Rejuvenate Biomed and SAS tap AI to develop disease-agnostic drug repurposing discovery tools

Clinical trial demonstrates the therapeutic potential of RJx-01 in sarcopenia

Positive results Phase 1b trial in sarcopenia

Committed to a sustainable future

Acknowledgements and investors

Clinical-stage biotech dedicated to the discovery and development of therapeutics
to delay the onset of multiple age-related diseases